Table 2.

Quantification of pRab10^Thr73 phosphorylation levels by immunoblotting and targeted mass-spectrometry—descriptive analysis of multiplexed immunoblotting of pRab10^Thr73/total Rab10 ratio normalized to healthy control DMSO neutrophil samples of at least two independent experiments with duplicate loading (≥ 4 data points per sample) and targeted mass-spectrometry measuring absolute pRab10^Thr73 occupancy (%) of two independent measurements including mean, standard deviation (SD), minimum and maximum for control, iPD and LRRK2 G2019S and R1441G mutation carriers

Multiplex immunoblotting normalized pRab10/total Rab10 (DMSO)	Controls (n = 32)	iPD (n = 26)	G2019S (n = 21)	R1441G (n = 20)
Mean (ratio)	1.00	0.94	1.06	4.61
SD	0.40	0.37	0.20	1.70
Minimum	0.11	0.21	0.53	1.80
Maximum	2.01	1.78	1.58	8.16

Targeted mass-spectrometry pRab10 (DMSO) occupancy	(n = 32)	(n = 26)	(n = 21)	(n = 20)
Mean (%)	1.52	1.61	1.90	6.60
SD	0.67	0.65	0.40	2.39
Minimum	0.20	0.20	1.01	2.85
Maximum	3.21	3.22	2.61	12.90

Segregation of LRRK2 mutation carriers according to clinical status did not reveal a statistical difference between mutation carriers with and without PD using unpaired t testing (PD vs NMC for LRRK2 G2019S and R1441G) but was not included in this table